Skip to content

Study · Animal study (in vivo) · rat · 2005

5 results

Vasoactive intestinal peptide modulates luteinizing hormone subunit gene expression in the anterior pituitary in female rat.

Gajewska A, Wolińska-Witort E, Kochman K

Brain research bulletin1 Oct 2005Cited by 2 (Europe PMC)

PMID16182940 (opens in a new tab)DOI10.1016/j.brainresbull.2005.07.007 (opens in a new tab)PepBankPUB-16182940
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In ovariectomized, oestrogen-primed female rats, pulsatile intracerebroventricular VIP decreased alpha subunit mRNA content in the pituitary gland.

    In plain wordsIn female rats, VIP given into the brain lowered the amount of LH alpha subunit mRNA in the pituitary.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreasePituitary alpha subunit mRNA content
    Study

    ratn: not reported in source

    Ovariectomized, oestrogen-pretreated female rats
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    5 nM · intracerebroventricular · 5 hAs given in this study (rat).

    Source sentences

    Summary
    Northern-blot analysis revealed that VIP microinjection resulted in a decreased alpha and LHbeta mRNA content in pituitary gland
    1 context sentence
    Summary · context
    Using a model based on intracerebroventricular pulsatile peptide(s) microinjections (1 pulse/h [10 microl/5 min] over 5 h) the effect of exogenous VIP (5 nM dose) microinjection on subunits mRNA content in ovariectomized/oestrogen-pretreated rats was studied.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In ovariectomized, oestrogen-primed female rats, pulsatile intracerebroventricular VIP decreased LHbeta subunit mRNA content in the pituitary gland.

    In plain wordsIn female rats, VIP given into the brain lowered the amount of LH beta subunit mRNA in the pituitary.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreasePituitary LHbeta subunit mRNA content
    Study

    ratn: not reported in source

    Ovariectomized, oestrogen-pretreated female rats
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    5 nM · intracerebroventricular · 5 hAs given in this study (rat).

    Source sentences

    Summary
    Northern-blot analysis revealed that VIP microinjection resulted in a decreased alpha and LHbeta mRNA content in pituitary gland
    1 context sentence
    Summary · context
    Using a model based on intracerebroventricular pulsatile peptide(s) microinjections (1 pulse/h [10 microl/5 min] over 5 h) the effect of exogenous VIP (5 nM dose) microinjection on subunits mRNA content in ovariectomized/oestrogen-pretreated rats was studied.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In ovariectomized, oestrogen-primed female rats, centrally given VIP exerted an inhibitory effect on LH release.

    In plain wordsIn female rats, VIP given into the brain reduced the release of LH.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseLH release
    Study

    ratn: not reported in source

    Ovariectomized, oestrogen-pretreated female rats
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    5 nM · intracerebroventricular · 5 hAs given in this study (rat).

    Source sentences

    Summary
    Moreover, obtained results indicated that centrally administered VIP might operate through its own receptor(s) because a receptor antagonist, VIP 6-28, blocked the inhibitory effect of VIP exerted on both LH subunit mRNA content and LH release.
    1 context sentence
    Summary · context
    Using a model based on intracerebroventricular pulsatile peptide(s) microinjections (1 pulse/h [10 microl/5 min] over 5 h) the effect of exogenous VIP (5 nM dose) microinjection on subunits mRNA content in ovariectomized/oestrogen-pretreated rats was studied.

Studies that did not test the peptide alone2

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 04AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism

    In female rats, the VIP-induced decrease in alpha and LHbeta mRNA depended on GnRH receptor activity, tested with the GnRH receptor antagonist antide.

    In plain wordsIn female rats, the drop in LH subunit mRNA after VIP depended on GnRH receptor activity.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableGnRH receptor dependence of the VIP effect on LH subunit mRNA
    Study

    ratn: not reported in source

    Ovariectomized, oestrogen-pretreated female rats
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    and this effect was dependent on GnRH receptor activity.
    1 context sentence
    Summary · context
    Using a model based on intracerebroventricular pulsatile peptide(s) microinjections (1 pulse/h [10 microl/5 min] over 5 h) the effect of exogenous VIP (5 nM dose) microinjection on subunits mRNA content in ovariectomized/oestrogen-pretreated rats was studied.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 05AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism

    In female rats, the VIP receptor antagonist VIP 6-28 blocked the inhibitory effect of VIP on LH subunit mRNA content and LH release.

    In plain wordsIn female rats, a VIP receptor blocker stopped VIP from lowering LH subunit mRNA and LH release.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableBlock of the VIP inhibitory effect by VIP receptor antagonist VIP 6-28
    Study

    ratn: not reported in source

    Ovariectomized, oestrogen-pretreated female rats
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    Moreover, obtained results indicated that centrally administered VIP might operate through its own receptor(s) because a receptor antagonist, VIP 6-28, blocked the inhibitory effect of VIP exerted on both LH subunit mRNA content and LH release.
    1 context sentence
    Summary · context
    Using a model based on intracerebroventricular pulsatile peptide(s) microinjections (1 pulse/h [10 microl/5 min] over 5 h) the effect of exogenous VIP (5 nM dose) microinjection on subunits mRNA content in ovariectomized/oestrogen-pretreated rats was studied.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.